Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease

• Ngā kaituhi matua: V. I. Ignatyeva (Author), S. V. Moiseev (Author), N. M. Bulanov (Author), E. A. Karovajkina (Author), A S. Moiseev (Author)
• Hōputu: Pukapuka
• I whakaputaina: IRBIS LLC, 2019-01-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Fabry disease (FD) is a severe lysosome storage disease caused by congenital deficiency of the enzyme α-galactosidase A and characterized by the risk of renal failure combined with cardiovascular and CNS complications. According to the currently available information, the early start of enzyme repla...